
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10393626/publications.pdf Version: 2024-02-01



DETED R RACH

#	Article	IF	CITATIONS
1	Real-World Use of Bone-Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer. Journal of the National Cancer Institute, 2022, 114, 419-426.	3.0	15
2	The Prescription Drug User Fee Act. Medical Care, 2022, Publish Ahead of Print, .	1.1	4
3	Validation of a Population-Based Data Source to Examine National Cancer Clinical Trial Participation. JAMA Network Open, 2022, 5, e223687.	2.8	4
4	Assessment of Outcomes Associated With the Use of Newly Approved Oncology Drugs in Medicare Beneficiaries. JAMA Network Open, 2021, 4, e210030.	2.8	21
5	Personal Payments from Pharmaceutical Companies to Authors of Oncology Clinical Practice Guidelines. Oncologist, 2021, 26, 771-778.	1.9	6
6	Mapping conflict of interests: scoping review. BMJ, The, 2021, 375, e066576.	3.0	14
7	Increasing Financial Payments From Industry to Medical Oncologists in the United States, 2014–2017. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, , 1-9.	2.3	5
8	Assessment of variation in 30â€day mortality following cancer surgeries among older adults across US hospitals. Cancer Medicine, 2020, 9, 1648-1660.	1.3	5
9	Review of Current Policy Strategies to Reduce US Cancer Drug Costs. Journal of Clinical Oncology, 2020, 38, 372-379.	0.8	18
10	Assessing whether cancer stage is needed to evaluate measures of hospital surgical performance. Journal of Evaluation in Clinical Practice, 2020, 26, 66-71.	0.9	2
11	The Accuracy and Usefulness of the National Comprehensive Cancer Network Evidence Blocks Affordability Rating. Pharmacoeconomics, 2020, 38, 737-745.	1.7	5
12	Commentary on Hsiue et al: Cost savings and data limitations of new cancer drug studies. Clinical Trials, 2020, 17, 126-128.	0.7	1
13	Understanding the Rewards of Successful Drug Development — Thinking Inside the Box. New England Journal of Medicine, 2020, 382, 473-480.	13.9	12
14	Use of Positron Emission Tomography Imaging: Another Nonbiological Source of Racial Disparities in US Cancer Care. Journal of the National Cancer Institute, 2020, 112, 1177-1178.	3.0	2
15	Changes in Drug List Prices and Amounts Paid by Patients and Insurers. JAMA Network Open, 2020, 3, e2028510.	2.8	16
16	Impact of provider volume on front-line chemotherapy guideline compliance and overall survival in elderly patients with advanced ovarian cancer. Gynecologic Oncology, 2020, 159, 418-425.	0.6	7
17	Trends in Female Representation on NCCN Guideline Panels. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1084-1086.	2.3	4
18	Association Between Clinical Value and Financial Cost of Cancer Treatments: A Cross-Sectional Analysis. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1349-1353.	2.3	0

#	Article	IF	CITATIONS
19	Association Between Clinical Value and Financial Cost of Cancer Treatments: A Cross-Sectional Analysis. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1349-1353.	2.3	9
20	The gender gap in critical care task force participation. Lancet Respiratory Medicine,the, 2019, 7, 566-567.	5.2	8
21	Preventive Services Offered in Executive Physicals at Top-Ranked Hospitals. JAMA - Journal of the American Medical Association, 2019, 322, 1101.	3.8	7
22	Cancer hospital advertising and outcomes: trust the messenger?. Lancet Oncology, The, 2019, 20, 760-762.	5.1	3
23	Prescription Drugs—List Price, Net Price, and the Rebate Caught in the Middle. JAMA - Journal of the American Medical Association, 2019, 321, 1563.	3.8	28
24	Female representation among US National Comprehensive Cancer Network guideline panel members. Lancet Oncology, The, 2019, 20, 327-329.	5.1	9
25	Practice Patterns for Older Adult Patients With Advanced Cancer: Physician Office Versus Hospital Outpatient Setting. Journal of Oncology Practice, 2019, 15, e30-e38.	2.5	4
26	Identifying Cancer-Directed Surgeries in Medicare Claims: A Validation Study Using SEER-Medicare Data. JCO Clinical Cancer Informatics, 2019, 3, 1-24.	1.0	13
27	Which Drug Prices Should Medicare Negotiate? A "Too Little―or "Too Late―Approach. New England Journal of Medicine, 2019, 381, 2084-2086.	13.9	4
28	Health Returns to Pharmaceutical Innovation in the Market for Oral Chemotherapy in Response to Insurance Coverage Expansion. American Journal of Health Economics, 2019, 5, 360-375.	1.4	2
29	Low-dose CT for lung cancer screening. Lancet Oncology, The, 2018, 19, e133-e134.	5.1	4
30	Value-Based Pricing for Drugs. JAMA - Journal of the American Medical Association, 2018, 319, 2165.	3.8	59
31	Medication overuse in oncology: current trends and future implications for patients and society. Lancet Oncology, The, 2018, 19, e200-e208.	5.1	33
32	Critical Choices: What Information Do Patients Want When Selecting a Hospital for Cancer Surgery?. Journal of Oncology Practice, 2018, 14, e505-e512.	2.5	11
33	Expansion of the Medicare 340B Payment Program. JAMA - Journal of the American Medical Association, 2018, 320, 2311.	3.8	3
34	Enhancing the Value of the ASCO Value Framework. MDM Policy and Practice, 2018, 3, 238146831877622.	0.5	2
35	National Coverage Analysis of CAR-T Therapies — Policy, Evidence, and Payment. New England Journal of Medicine, 2018, 379, 1396-1398.	13.9	21
36	Surrogate Markers and the Association of Low-Dose CT Lung Cancer Screening With Mortality. JAMA Oncology, 2018, 4, 1006.	3.4	3

#	Article	IF	CITATIONS
37	Race, Ethnicity, Health Insurance, and Mortality in Older Survivors of Critical Illness. Critical Care Medicine, 2017, 45, e583-e591.	0.4	15
38	Association of Prescription Drug Price Rebates in Medicare Part D With Patient Out-of-Pocket and Federal Spending. JAMA Internal Medicine, 2017, 177, 1185.	2.6	54
39	FDA Approval of Tisagenlecleucel. JAMA - Journal of the American Medical Association, 2017, 318, 1861.	3.8	136
40	Association of Hospital Costs With Complications Following Total Gastrectomy for Gastric Adenocarcinoma. JAMA Surgery, 2017, 152, 953.	2.2	35
41	Raising the Dose and Raising the Cost: The Case of Pembrolizumab in Lung Cancer. Journal of the National Cancer Institute, 2017, 109, .	3.0	9
42	Physician's Office and Hospital Outpatient Setting in Oncology: It's About Prices, Not Use. Journal of Oncology Practice, 2017, 13, 4-5.	2.5	4
43	ReCAP: Hospitalizations in Older Adults With Advanced Cancer: The Role of Chemotherapy. Journal of Oncology Practice, 2016, 12, 151-152.	2.5	25
44	Physician-Driven Variation in Nonrecommended Services Among Older Adults Diagnosed With Cancer. JAMA Internal Medicine, 2016, 176, 1541.	2.6	44
45	Overspending driven by oversized single dose vials of cancer drugs . BMJ, The, 2016, 352, i788.	3.0	109
46	Walking the Tightrope Between Treatment Efficacy and Price. Journal of Clinical Oncology, 2016, 34, 889-890.	0.8	10
47	Provider Differences in Use of Implanted Ports in Older Adults With Cancer. Medical Care, 2015, 53, 646-652.	1.1	9
48	Comorbidities, smoking status, and life expectancy among individuals eligible for lung cancer screening. Cancer, 2015, 121, 4341-4347.	2.0	59
49	Pricing in the Market for Anticancer Drugs. Journal of Economic Perspectives, 2015, 29, 139-162.	2.7	379
50	Ramucirumab for Colon Cancer and the Problem of Rising Prices Independent of Benefits. Oncologist, 2015, 20, 983-984.	1.9	8
51	Payer and Policy Maker Steps to Support Value-Based Pricing for Drugs. JAMA - Journal of the American Medical Association, 2015, 314, 2503.	3.8	66
52	New Math on Drug Cost-Effectiveness. New England Journal of Medicine, 2015, 373, 1797-1799.	13.9	63
53	Complications Associated With Use of Long-Term Central Venous Catheters Among Commercially Insured Women With Breast Cancer. Journal of Oncology Practice, 2015, 11, 505-510.	2.5	4
54	Hospital Volume, Complications, and Cost of Cancer Surgery in the Elderly. Journal of Clinical Oncology, 2015, 33, 107-114.	0.8	97

#	Article	IF	CITATIONS
55	Bilateral Mastectomy versus Breast-Conserving Surgery for Early-Stage Breast Cancer. Plastic and Reconstructive Surgery, 2015, 135, 1518-1526.	0.7	114
56	Wide Variation In Payments For Medicare Beneficiary Oncology Services Suggests Room For Practice-Level Improvement. Health Affairs, 2015, 34, 601-608.	2.5	25
57	Risk Adjusting Survival Outcomes in Hospitals That Treat Patients With Cancer Without Information on Cancer Stage. JAMA Oncology, 2015, 1, 1303.	3.4	106
58	Long-Term Central Venous Catheter Use and Risk of Infection in Older Adults With Cancer. Journal of Clinical Oncology, 2014, 32, 2351-2356.	0.8	25
59	The 340B Drug Discount Program: Hospitals Generate Profits By Expanding To Reach More Affluent Communities. Health Affairs, 2014, 33, 1786-1792.	2.5	51
60	Improving Outpatient Oncology Practice: Several Steps Into a Long Journey. Journal of Oncology Practice, 2014, 10, 355-356.	2.5	0
61	Indication-Specific Pricing for Cancer Drugs. JAMA - Journal of the American Medical Association, 2014, 312, 1629.	3.8	107
62	Prevalence of Off-Label Use and Spending in 2010 Among Patent-Protected Chemotherapies in a Population-Based Cohort of Medical Oncologists. Journal of Clinical Oncology, 2013, 31, 1134-1139.	0.8	113
63	Practice-Changing Strategies to Deliver Affordable, High-Quality Cancer Care: Summary of an Institute of Medicine Workshop. Journal of Oncology Practice, 2013, 9, 54s-59s.	2.5	7
64	Cost Consequences of the 340B Drug Discount Program. JAMA - Journal of the American Medical Association, 2013, 309, 1995.	3.8	48
65	Visions of Hope in Cancer: Focus on Infrastructure. JAMA Internal Medicine, 2013, 173, 979.	2.6	1
66	Perilous potential: The chance to save lives, or lose them, through low dose computed tomography screening for lung cancer. Journal of Surgical Oncology, 2013, 108, 287-288.	0.8	8
67	Changes in the availability of screening mammography, 2000–2010. Cancer, 2013, 119, 3847-3853.	2.0	17
68	A Prognostic Model for 6-Month Mortality in Elderly Survivors of Critical Illness. Chest, 2013, 143, 910-919.	0.4	56
69	Lung Cancer Screening: Response. Chest, 2013, 144, 1737-1738.	0.4	0
70	Screening for Lung Cancer. Chest, 2013, 143, e78S-e92S.	0.4	399
71	A Paradigm Shift in U.S. Breast Reconstruction. Plastic and Reconstructive Surgery, 2013, 131, 15-23.	0.7	745
72	Infused Chemotherapy Use in the Elderly After Patent Expiration. Journal of Oncology Practice, 2012, 8, e18s-e23s.	2.5	7

#	Article	IF	CITATIONS
73	The Influence of Sociodemographic Factors and Hospital Characteristics on the Method of Breast Reconstruction, Including Microsurgery. Plastic and Reconstructive Surgery, 2012, 129, 1071-1079.	0.7	110
74	When the Average Applies to No One: Personalized Decision Making About Potential Benefits of Lung Cancer Screening. Annals of Internal Medicine, 2012, 157, 571.	2.0	75
75	Benefits and Harms of CT Screening for Lung Cancer. JAMA - Journal of the American Medical Association, 2012, 307, 2418.	3.8	1,057
76	Association Between Quality of Care and the Sociodemographic Composition of Physicians' Patient Panels: A Repeat Cross-Sectional Analysis. Journal of General Internal Medicine, 2011, 26, 987-994.	1.3	7
77	Estimating Individual Risk for Lung Cancer. Seminars in Respiratory and Critical Care Medicine, 2011, 32, 003-009.	0.8	21
78	Episode-Based Payment For Cancer Care: A Proposed Pilot For Medicare. Health Affairs, 2011, 30, 500-509.	2.5	51
79	Inconsistencies in Findings From the Early Lung Cancer Action Project Studies of Lung Cancer Screening. Journal of the National Cancer Institute, 2011, 103, 1002-1006.	3.0	15
80	A Decade of Mortality Reductions in Major Oncologic Surgery. Medical Care, 2010, 48, 1041-1049.	1.1	106
81	Geographic Access and the Use of Screening Mammography. Medical Care, 2010, 48, 349-356.	1.1	87
82	Physician Visits Prior to Treatment for Clinically Localized Prostate Cancer. Archives of Internal Medicine, 2010, 170, 440.	4.3	145
83	Pem and the Cost of Multicycle Maintenance. Journal of Thoracic Oncology, 2010, 5, 1111-1112.	0.5	17
84	A Map to Bad Policy — Hospital Efficiency Measures in the Dartmouth Atlas. New England Journal of Medicine, 2010, 362, 569-574.	13.9	51
85	Commentary: Medicare's 2006 Oncology Demonstration Project: Lost in Translation?. Journal of Oncology Practice, 2010, 6, 59-60.	2.5	1
86	Cancer's Next Frontier. JAMA - Journal of the American Medical Association, 2010, 303, 1086.	3.8	136
87	Primary Care Physicians' Links to Other Physicians Through Medicare Patients: The Scope of Care Coordination. Annals of Internal Medicine, 2009, 150, 236.	2.0	188
88	Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs. New England Journal of Medicine, 2009, 360, 626-633.	13.9	371
89	Smoking as a Factor in Causing Lung Cancer. JAMA - Journal of the American Medical Association, 2009, 301, 539.	3.8	18
90	Is our natural-history model of lung cancer wrong?. Lancet Oncology, The, 2008, 9, 693-697.	5.1	56

#	Article	IF	CITATIONS
91	Disenrollment From Medicare Managed Care Among Beneficiaries With and Without a Cancer Diagnosis. Journal of the National Cancer Institute, 2008, 100, 1013-1021.	3.0	8
92	Overdiagnosis in lung cancer: different perspectives, definitions, implications. Thorax, 2008, 63, 298-300.	2.7	26
93	Response to "CT Screening for Lung Cancer: Update 2007― Oncologist, 2008, 13, 608-609.	1.9	3
94	Untreated Patients in "CT Screening for Lung Cancer: Update 2007― Oncologist, 2008, 13, 1030-1032.	1.9	5
95	Do Surgical Quality Gaps Cause Healthcare Disparities?. Medical Care, 2008, 46, 889-892.	1.1	4
96	Lung Cancer Screening. Journal of the National Comprehensive Cancer Network: JNCCN, 2008, 6, 271-275.	2.3	9
97	Costs of Cancer Care: A View From the Centers for Medicare & Medicaid Services. Journal of Clinical Oncology, 2007, 25, 187-190.	0.8	35
98	Screening for Lung Cancer. Chest, 2007, 132, 69S-77S.	0.4	139
99	Care Patterns in Medicare and Their Implications for Pay for Performance. New England Journal of Medicine, 2007, 356, 1130-1139.	13.9	450
100	Computed Tomography Screening and Lung Cancer Outcomes. JAMA - Journal of the American Medical Association, 2007, 297, 953.	3.8	490
101	Potentially Avoidable Hospitalizations for COPD and Pneumonia. Medical Care, 2007, 45, 562-570.	1.1	45
102	Fragmentation of Care for Frequently Hospitalized Urban Residents. Medical Care, 2006, 44, 560-567.	1.1	63
103	The First Months of the Prescription-Drug Benefit — A CMS Update. New England Journal of Medicine, 2006, 354, 2312-2314.	13.9	34
104	Validation of a Model of Lung Cancer Risk Prediction Among Smokers. Journal of the National Cancer Institute, 2006, 98, 637-640.	3.0	66
105	The Association between Hospital Volume and Total Shoulder Arthroplasty Outcomes. Clinical Orthopaedics and Related Research, 2005, 432, 132-137.	0.7	77
106	Using Practice Guidelines to Assess Cancer Care Quality. Journal of Clinical Oncology, 2005, 23, 9041-9043.	0.8	22
107	A Prescription for a Modern Medicare Program. New England Journal of Medicine, 2005, 353, 2733-2735.	13.9	26
108	Delivery of Preventive Services to Older Adults by Primary Care Physicians. JAMA - Journal of the American Medical Association, 2005, 294, 473.	3.8	243

#	Article	IF	CITATIONS
109	Primary Care Physicians Who Treat Blacks and Whites. New England Journal of Medicine, 2004, 351, 575-584.	13.9	865
110	Lung Cancer in US Women. JAMA - Journal of the American Medical Association, 2004, 291, 1763.	3.8	220
111	Resurrecting Treatment Histories of Dead Patients. JAMA - Journal of the American Medical Association, 2004, 292, 2765.	3.8	220
112	Benchmarking Lung Cancer Mortality Rates in Current and Former Smokers. Chest, 2004, 126, 1742-1749.	0.4	44
113	Surgeon volume compared to hospital volume as a predictor of outcome following primary colon cancer resection. Journal of Surgical Oncology, 2003, 83, 68-78.	0.8	202
114	Perspectives on the Value of American Society of Clinical Oncology Clinical Guidelines as Reported by Oncologists and Health Maintenance Organizations. Journal of Clinical Oncology, 2003, 21, 937-941.	0.8	36
115	Variations in Lung Cancer Risk Among Smokers. Journal of the National Cancer Institute, 2003, 95, 470-478.	3.0	547
116	Adherence to Surveillance Among Patients With Superficial Bladder Cancer. Journal of the National Cancer Institute, 2003, 95, 588-597.	3.0	127
117	Screening for Lung Cancer*. Chest, 2003, 123, 72S-82S.	0.4	242
118	Screening for Lung Cancer*. Chest, 2003, 123, 83S-88S.	0.4	86
119	The Effect of Clustering of Outcomes on the Association of Procedure Volume and Surgical Outcomes. Annals of Internal Medicine, 2003, 139, 658.	2.0	280
120	Consider saying yes *. Critical Care Medicine, 2003, 31, 320-321.	0.4	19
121	Adjuvant Chemotherapy Use for Medicare Beneficiaries With Stage II Colon Cancer. Journal of Clinical Oncology, 2002, 20, 3999-4005.	0.8	226
122	State Expenditures for Tobacco-Control Programs and the Tobacco Settlement. New England Journal of Medicine, 2002, 347, 1080-1086.	13.9	66
123	Variations in Morbidity after Radical Prostatectomy. New England Journal of Medicine, 2002, 346, 1138-1144.	13.9	800
124	Identifying and Measuring Hospital Characteristics Using the SEER-Medicare Data and Other Claims-Based Sources. Medical Care, 2002, 40, IV-96-IV-103.	1.1	51
125	Overview of the SEER-Medicare Data. Medical Care, 2002, 40, IV-3-IV-18.	1.1	712
126	Patient Demographic and Socioeconomic Characteristics in the SEER-Medicare Database. Medical Care, 2002, 40, IV-19-IV-25.	1.1	200

#	Article	IF	CITATIONS
127	Hospital and Surgeon Procedure Volume as Predictors of Outcome Following Rectal Cancer Resection. Annals of Surgery, 2002, 236, 583-592.	2.1	306
128	Survival of Blacks and Whites After a Cancer Diagnosis. JAMA - Journal of the American Medical Association, 2002, 287, 2106.	3.8	444
129	The epidemiology and costs of chronic critical illness. Critical Care Clinics, 2002, 18, 461-476.	1.0	197
130	Impact of Infection by Vancomycin-Resistant Enterococcus on Survival and Resource Utilization for Patients With Leukemia. Infection Control and Hospital Epidemiology, 2002, 23, 471-474.	1.0	18
131	Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Medical Care, 2002, 40, IV-3-18.	1.1	1,089
132	Who Gets Adjuvant Treatment for Stage II and III Rectal Cancer? Insight From Surveillance, Epidemiology, and End Results–Medicare. Journal of Clinical Oncology, 2001, 19, 3712-3718.	0.8	147
133	Identification of poor prognostic features among patients requiring mechanical ventilation after hematopoietic stem cell transplantation. Blood, 2001, 98, 3234-3240.	0.6	106
134	Predicting Mortality in Patients Suffering From Prolonged Critical Illness. Chest, 2001, 120, 928-933.	0.4	62
135	Age and Adjuvant Chemotherapy Use After Surgery for Stage III Colon Cancer. Journal of the National Cancer Institute, 2001, 93, 850-857.	3.0	450
136	Management of Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Summary and Appraisal of Published Evidence. Annals of Internal Medicine, 2001, 134, 600.	2.0	230
137	The Influence of Hospital Volume on Survival after Resection for Lung Cancer. New England Journal of Medicine, 2001, 345, 181-188.	13.9	656
138	Identifying Providers of Care to Individuals with Human Immunodeficiency Virus for a Mail Survey Using a Prescription Tracking Database. Journal of Clinical Epidemiology, 1999, 52, 147-150.	2.4	2
139	Racial Differences in the Treatment of Early-Stage Lung Cancer. New England Journal of Medicine, 1999, 341, 1198-1205.	13.9	944
140	The Relation Between Physician Experience and Patterns of Care for Patients With AIDS-Related Pneumocystis carinii Pneumonia. Chest, 1999, 115, 1563-1569.	0.4	9